Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Shares Outstanding (Diluted Average) (2020 - 2023)

Historic Shares Outstanding (Diluted Average) for Tg Therapeutics (TGTX) over the last 4 years, with Q2 2023 value amounting to $141.5 million.

  • Tg Therapeutics' Shares Outstanding (Diluted Average) rose 498.88% to $141.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was $141.5 million, marking a year-over-year increase of 498.88%. This contributed to the annual value of $135.4 million for FY2022, which is 241.15% up from last year.
  • According to the latest figures from Q2 2023, Tg Therapeutics' Shares Outstanding (Diluted Average) is $141.5 million, which was up 498.88% from $140.3 million recorded in Q1 2023.
  • Tg Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $141.5 million during Q2 2023, with a 5-year trough of $115.3 million in Q4 2020.
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $134.4 million (2022), whereas its average is $133.2 million.
  • In the last 5 years, Tg Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 1464.36% in 2021 and then surged by 189.68% in 2022.
  • Over the past 4 years, Tg Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $115.3 million in 2020, then rose by 14.64% to $132.2 million in 2021, then increased by 2.41% to $135.4 million in 2022, then rose by 4.5% to $141.5 million in 2023.
  • Its Shares Outstanding (Diluted Average) was $141.5 million in Q2 2023, compared to $140.3 million in Q1 2023 and $135.4 million in Q4 2022.